Peripheral serum copper metabolite levels measured by ultrafiltration aid in the clinical screening of Alzheimer’s disease
- 1Department of Psychiatry, Zhejiang Key Laboratory of Drug Addiction & Brain Health, Affiliated Kangning Hospital of Ningbo University (Ningbo Kangning Hospital)
Abstract
Background: The number of patients with Alzheimer’s disease (AD) is increasing, yet misdiagnosis remains common and early accurate diagnosis is lacking. Previous studies have suggested abnormalities in peripheral serum copper levels in AD patients. This study sought to explore the diagnostic value of peripheral serum copper-related biomarkers for clinically diagnosed AD.
Methods: Peripheral serum samples were collected from 115 clinically diagnosed AD patients and 96 healthy controls (HC). A preliminary experiment on five samples determined the use of a 10 kDa ultrafiltration membrane. Four serum copper parameters—serum total copper (tot-Cu), free copper (free-Cu), serum immunological ceruloplasmin concentration (iCp), and ceruloplasmin enzymatic activity (eCp)—were quantitatively measured in all samples using ultrafiltration, atomic absorption spectrometry, and ELISA.
Results: Peripheral tot-Cu and free-Cu levels in clinically diagnosed AD patients were significantly elevated in the early stage of the disease, while iCp, eCp, and the iCp/eCp ratio were significantly decreased. The diagnostic efficacy of tot-Cu and free-Cu for these Alzheimer’s disease patients was significantly higher than that of the Mini-Mental State Examination (MMSE) score. Nevertheless, these indicators could not distinguish different severity stages of clinically phenotyped AD.
Conclusion: Our results indicate that tot-Cu or free-Cu holds promise as biomarkers for the clinical screening of AD; peripheral copper metabolic dysregulation may be involved in the pathogenesis of clinically phenotyped AD.
Related
- [Recent advances of affinity ultrafiltration-liquid chromatography-mass spectrometry in screening natural active substances].
- Alzheimer's Disease Biomarkers Measured by Capillary Blood Collection Versus Venous Plasma and Cerebrospinal Fluid
- No evidence that serum metabolite slopes improve held-out prediction of clinical progression in the Alzheimer’s disease neuroimaging initiative
- Stable episodic memory and higher education do not influence the rate of Alzheimer's disease pathology as measured by plasma p‐tau217
- Plasma β‐synuclein associates with hippocampal synaptic density measured with [11C]UCB‐J PET and plasma tau markers in Alzheimer's disease
BibTeX
@article{zhang2026peripheral,
title = {{Peripheral serum copper metabolite levels measured by ultrafiltration aid in the clinical screening of Alzheimer’s disease}},
author = {Yi Zhang and Longhui Li and Houxian Ouyang and Zheng Zhao and Xi Mei and Conglong Qiu},
journal = {Frontiers in Psychiatry},
year = {2026},
month = oct,
doi = {10.3389/fpsyt.2026.1954419},
url = {https://www.frontiersin.org/articles/10.3389/fpsyt.2026.1954419/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Peripheral serum copper metabolite levels measured by ultrafiltration aid in the clinical screening of Alzheimer’s disease
AU - Yi Zhang
AU - Longhui Li
AU - Houxian Ouyang
AU - Zheng Zhao
AU - Xi Mei
AU - Conglong Qiu
PY - 2026
DA - 2026/10/14
JO - Frontiers in Psychiatry
DO - 10.3389/fpsyt.2026.1954419
UR - https://www.frontiersin.org/articles/10.3389/fpsyt.2026.1954419/full
AB - Background: The number of patients with Alzheimer’s disease (AD) is increasing, yet misdiagnosis remains common and early accurate diagnosis is lacking. Previous studies have suggested abnormalities in peripheral serum copper levels in AD patients. This study sought to explore the diagnostic value of peripheral serum copper-related biomarkers for clinically diagnosed AD. Methods: Peripheral serum samples were collected from 115 clinically diagnosed AD patients and 96 healthy controls (HC). A preliminary experiment on five samples determined the use of a 10 kDa ultrafiltration membrane. Four serum copper parameters—serum total copper (tot-Cu), free copper (free-Cu), serum immunological ceruloplasmin concentration (iCp), and ceruloplasmin enzymatic activity (eCp)—were quantitatively measured in all samples using ultrafiltration, atomic absorption spectrometry, and ELISA. Results: Peripheral tot-Cu and free-Cu levels in clinically diagnosed AD patients were significantly elevated in the early stage of the disease, while iCp, eCp, and the iCp/eCp ratio were significantly decreased. The diagnostic efficacy of tot-Cu and free-Cu for these Alzheimer’s disease patients was significantly higher than that of the Mini-Mental State Examination (MMSE) score. Nevertheless, these indicators could not distinguish different severity stages of clinically phenotyped AD. Conclusion: Our results indicate that tot-Cu or free-Cu holds promise as biomarkers for the clinical screening of AD; peripheral copper metabolic dysregulation may be involved in the pathogenesis of clinically phenotyped AD.
SN - 1664-0640
ER -